AMAG Pharma (AMAG) Posts Q3 Loss of $1.88/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
AMAG Pharmaceuticals Announces Third Quarter 2018 Financial Results and Provides Corporate Update
November 1, 2018 7:00 AM EDTAchieved strong third quarter financial performance and increased full year 2018 guidance
Acquired AMAG-423 for severe preeclampsia, reaffirming the company's focus on deliveringinnovative therapies that address unmet medical needs
Conference call scheduled for 8:00 a.m. ET today
WALTHAM, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today reported unaudited consolidated financial results for the third quarter and year-to-date periods ended September 30, 2018. As a result of the sale of Cord Blood Registry® (CBR), which closed on August 6, 2018, CBR's results... More
